SRX 0.00% $33.55 sirtex medical limited

article on sir-spheres

  1. 221 Posts.
    http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=70977

    Encouraging facts from the article in the link above:
    - Survival rate of over 50% (26 out of 44) at 6 months follow up
    - Out of the 27 patients who had liver metastases, 8 came from primary breast cancer. Sir-spheres is currently approved for liver metastases spread from primary colonrectal cancer. So there is a large untapped market there.
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.